Vertex Pharmaceuticals VRTX TRIKAFTA/KAFTRIO — Product revenues, net

Other product segments

Similar metrics at other companies

INSMBRINSUPRI — Product revenues, net

$309.17M—

COLLAzstarys — Product revenues, net

$12.91M—

COLLBelbuca — Product revenues, net

$57.67M+9.6%

COLLSymproic — Product revenues, net

$3.02M-18.9%

COLLJornay PM — Product revenues, net

$46.06M+41.2%

COLLNucynta ER — Product revenues, net

$15.72M-21.2%

FAQ

What is Vertex Pharmaceuticals's TRIKAFTA/KAFTRIO — product revenues, net?

Vertex Pharmaceuticals (VRTX) reported TRIKAFTA/KAFTRIO — product revenues, net of $2.5B in Q2 2026.

How has Vertex Pharmaceuticals's TRIKAFTA/KAFTRIO — product revenues, net changed year-over-year?

Vertex Pharmaceuticals's TRIKAFTA/KAFTRIO — product revenues, net decreased by 2.1% year-over-year, from $2.55B to $2.5B.

What is the long-term trend for Vertex Pharmaceuticals's TRIKAFTA/KAFTRIO — product revenues, net?

Over 4 years (2021 to 2025), Vertex Pharmaceuticals's TRIKAFTA/KAFTRIO — product revenues, net has grown at a 16.0% compound annual growth rate (CAGR), from $5.7B to $10.31B.

What does TRIKAFTA/KAFTRIO — product revenues, net mean?

This metric represents the net sales generated from the company's primary cystic fibrosis therapeutic franchise after accounting for returns, discounts, and rebates. It serves as the core revenue driver for the business, reflecting the market adoption and patient utilization of the company's flagship small-molecule treatment portfolio. Monitoring this figure provides insight into the commercial success and competitive positioning of the company's most critical therapeutic asset.